Will the Private Medical Cannabis Market Shrink if NHS Access Opens Up?

As medical cannabis gains legal recognition across the UK, discussions about the future of its market intensify. A key question looming over patients and providers alike is whether the private medical cannabis market will shrink if NHS access becomes more widely available. To unpack this, we need to separate the legality of cannabis prescriptions from the reality of patient access and funding, scrutinise the roles of who can prescribe, and understand the regulatory environment—especially the role of video consultations, remote prescribing, and Care Quality Commission (CQC) oversight in England.

Separating Legality from Real-World Access

Medical cannabis has been legal for prescription since November 2018 across the UK. However, legality does not automatically ensure widespread NHS availability. The NHS access landscape remains limited, resulting in a persistent 'two-tier' system where many patients turn to private healthcare providers to obtain cannabis-based products for medicinal use (CBPMs).

In practice:

  • Legality: Medical cannabis prescriptions are lawful when prescribed by specialist clinicians registered on the General Medical Council (GMC) Specialist Register.
  • Access: NHS prescribing of CBPMs remains rare, typically reserved for exceptional cases, due largely to clinical commissioning policies and funding constraints.

This gap between legality and access drives the private market, which offers speed and choice but at a cost to patients.

The NHS Funding Gap and Private Market Reality

The NHS faces significant funding challenges. Central to the slow uptake of medical cannabis on the NHS is the lack of an established funding stream and clear, consistent prescribing guidelines. NHS Clinical Commissioning Groups (CCGs) and their mainland devolved counterparts have yet to uniformly endorse CBPMs, citing limited robust evidence and cost-effectiveness concerns.

In consequence, many patients who benefit from medical cannabis turn to the private sector. Private clinics typically offer:

  • Faster consultations:
  • A broader range of products and formulations:
  • Choice in prescribers:

However, hallmark issues persist in the private sector:

  • Patients often report a lack of transparent consultation and prescription pricing. Clinics frequently omit clear costs or disguise them within arbitrary package deals, making informed decisions difficult.
  • The overall financial burden remains higher—prescriptions and follow-up appointments can cost hundreds of pounds, contrasting with subsidised NHS provision.

Who Can Prescribe Medical Cannabis and Why It Matters

NHS regulations stipulate that only medical specialists registered on the GMC Specialist Register—typically in areas such as pain medicine, neurology, or palliative care—can prescribe medical cannabis. The rationale is twofold:

  1. Expertise: Prescribers require detailed knowledge of complex clinical conditions and potential drug interactions.
  2. Regulatory standards: Ensuring responsible prescribing reflecting evidence-based medicine and patient safety.

While anyone registered with the GMC who holds a licence to practise can technically prescribe, most rely on specialist advice or direct specialist prescribing due to complicated clinical governance around CBPMs. This requirement explains why most private clinics advertise access to GMC-registered specialists and why remote prescribing arrangements must be mdt medical review process carefully declared and regulated, particularly in England.

Regulation and CQC Oversight in England

Private providers of medical cannabis in England operate under the scrutiny of the Care Quality Commission (CQC). This introduces specific duties including:

  • Notification of remote prescribing: Any provider using video consultations or issuing prescriptions without face-to-face contact must declare these practices to the CQC.
  • Standards of care quality: Including safe prescribing, patient confidentiality, and appropriate follow-up.
  • Inspection and enforcement: Providers may face inspection or sanctions for non-compliance.

These mechanisms increase patient protection but do not eliminate challenges linked to cost transparency or uniform prescribing standards. Notably, in Wales, Scotland, and Northern Ireland different regulatory bodies and frameworks apply, which can complicate the picture for cross-border private providers.

Video Consultations and Remote Prescribing: Modernising Access

Video consultations and remote prescribing have become integral tools facilitating private medical cannabis provision. Especially since the COVID-19 pandemic, clinics have scaled up video-based assessments, which offer:

  • Convenience and speed
  • Access for patients living far from specialist centres
  • Reduced infection risks

However, in England, any use of these must be transparent and declared to the CQC, safeguarding patient safety. That said, a common oversight among private clinics is failing to fully disclose:

  • Consultation prices: Clearly stating fees is essential to avoid misleading patients.
  • Prescription costs: Often omitted from promotional material, despite being a significant expense.

Patients considering private routes should demand upfront, itemised pricing information covering initial consultation, follow-ups, and medication costs to avoid unexpected financial burdens.

Will NHS Prescribing Shrink the Private Market?

The question remains: if NHS access expands, will the private medical cannabis market shrink? The answer is nuanced.

Factors Supporting a Shrinking Private Market

  • Improved NHS prescribing pathways: If more clinicians on the GMC Specialist Register prescribe within the NHS, fewer patients might seek private alternatives.
  • Better NHS funding: Widespread reimbursement and commissioning could reduce the out-of-pocket cost for patients.

Factors Maintaining a Two-Tier, Diverse Market

  • The speed and choice advantage of private providers: NHS prescribing pathways tend to be cautious, limiting product choice to established formulations.
  • Geographical variable NHS access: Regional commissioning differences mean some patients may still find NHS access difficult, turning to the private sector.
  • Regulatory safeguards and specialist prescribing rules: Some patients prefer the privacy and perceived expertise of private clinics.

Therefore, while NHS expansion may capture some patients, the private market likely remains a critical component for those prioritising speed, choice, or facing gaps in NHS provision.

Summary Checklist: What Patients Should Know

Key Consideration What to Verify Legality vs Access Legal prescriptions do not guarantee NHS availability; check local NHS policies. Prescriber Credentials Prescriber should be on GMC Specialist Register; confirm clinical expertise. Consultation and Prescription Costs Ask for full, itemised pricing before committing to private providers. Use of Video Consultations Check if the provider declares remote prescribing to CQC (England only). NHS vs Private Access Evaluate timelines, product options, and funding differences between routes. Regulation and Patient Safeguards Verify provider registration with relevant regulators (CQC in England, etc.).

Conclusion

While increased NHS medical cannabis prescribing would likely reduce demand on the private market, several structural and regulatory factors suggest the private sector will remain relevant. The private market’s speed, choice, and flexibility—combined with ongoing NHS funding and commissioning gaps—make a two-tier system likely to persist in the foreseeable future.

Patients should carefully weigh available options, confirm the credentials of prescribers, and demand transparent pricing before engaging with private clinics, particularly those offering video consultations and remote prescribing. This approach ensures safe, informed choices within a complex and evolving healthcare landscape.